Alcami to Provide Manufacturing Services for Trevena’s Pain Management Injection

News
Article

Alcami will provide services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.

Alcami, a US-based contract development and manufacturing organization, announced on Aug. 26, 2020 that it will provide commercial manufacturing services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.

“For Alcami, this is another example of our ability to partner with customers to provide comprehensive support services from development through commercial approval," said Walt Kaczmarek, CEO of Alcami, in the press release. "We congratulate Trevena on their novel product offering and important advancement in pain therapy and are proud to offer our expertise and support.”

Source: Alcami

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content